CD8A and neoplasm: All these results showed that talniflumate is able to evoke an anti-tumoral immune response in syngeneic PDAC mouse models, however only the combination treatment of talniflumate with standard therapy was able to concomitantly increase the number CD8+ T cells infiltrating the tumors and produce a significant tumor volume shrinkage (Figs. 5a, b and 6a–c).